About Nectar Biopharma Private Limited
Data last updated: 18 December 2025
Nectar Biopharma Private Limited is a private limited company based in Mumbai, Maharashtra, India. It specialises in pharmaceutical retail and distribution, a part of the broader pharmaceuticals sector. Incorporated on 13 April 2015, the company has been in operation for over 11 years.
Registered with ROC Mumbai under CIN U24100DL2015PTC278972.
Capital: an authorised share capital of ₹1 Cr and a paid-up capital of ₹1 Cr. It is led by directors including Rajinder Sharma and Aryan Goyal.
Last AGM: 16 September 2024. Financial statements filed for year ended 31 March 2024. Office: Office No.101 1St Floor Udyog Bhavan Sonawala Lane Goregaon East, Mumbai, Maharashtra, India – 400063.
As per the financials filed for FY 2025, the company reported a revenue of ₹2.6 Cr, a decline of 38% compared to the previous year.
The company has a workforce of approximately 2 employees as per the latest available data.
The company is associated with 1 brand - Nectar Biopharma. As per MCA filings, the company has satisfied charges of ₹22.65 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website necbio.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media**************
-
Registered AddressOffice No.101 1St Floor Udyog Bhavan Sonawala Lane Goregaon East, Mumbai, Maharashtra, India – 400063
-
IndustryPharma, Pharmaceutical Retailers & Distributors
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Nectar Biopharma Private Limited
Nectar Biopharma Private Limited has one previous CIN (Corporate Identification Number): U24100DL2015PTC278972. The current CIN is U24100MH2015PTC314118, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24100MH2015PTC314118 | Current |
| U24100DL2015PTC278972 | Previous |
Associated Brands with Nectar Biopharma Private Limited
Nectar Biopharma Private Limited operates one associated brand: Nectar Biopharma. These brands represent Nectar Biopharma Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Markets prescription drugs, OTC products, and medical solutions globally. | necbio.com |
Competitors & Alternatives of Nectar Biopharma Private Limited
Brands and companies operating in the same space as Nectar Biopharma Private Limited include Pfizer, Entero Healthcare, AmerisourceBergen and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Pfizer
|
Pharmaceutical products for treating multiple diseases are provided. | New York, United States, United States | 1849 |
Entero Healthcare
|
India's leading healthcare products distribution platform | Mumbai, India, India | 2018 |
AmerisourceBergen
|
Pharmaceutical distribution and supply chain services are provided globally. | Chesterbrook, United States, United States | 1985 |
Keimed
|
Temperature-sensitive medicines are distributed via cold chain logistics by Keimed. | Hyderabad, India, India | 2000 |
EBOS Group
|
Wholesaler & distributor of healthcare, medical, and pharmaceutical products | Docklands, Australia, Australia | 1922 |
Target Healthcare
|
Distributor of pharmaceutical products | East Kilbride, United Kingdom, United Kingdom | 2012 |
CHEPLAPHARM
|
Branded pharmaceutical products are developed, marketed, and distributed globally. | Mesekenhagen, Germany, Germany | 1998 |
Sandor Medicaids
|
Provider of medical equipment, devices, and drugs distribution services | Hyderabad, India, India | 1995 |
NEUCA
|
Wholesale distribution of pharmaceuticals is managed by NEUCA in Poland. | Torun, Poland, Poland | 1990 |
Renee
|
Diversified drugs are distributed by Renee in the United States. | Los Angeles, United States, United States | 2021 |
Business Activity of Nectar Biopharma Private Limited
Nectar Biopharma Private Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
Board of Directors of Nectar Biopharma Private Limited
Nectar Biopharma Private Limited is currently managed by 3 directors, with 9 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Rajinder Sharma
Also directs:
Nureca Limited, Nureca Technologies Private Limited
|
Director | 25 Jul 2022 | 3 Years 11 Months | Current |
| Aryan Goyal | Director | 27 Sep 2021 | 4 Years 9 Months | Current |
|
Saurabh Goyal
Also directs:
Nureca Limited, Trumom Private Limited, Nureca Technologies Private Limited and 2 more
|
Director | 14 Mar 2018 | 8 Years 3 Months | Current |
Financials of Nectar Biopharma Private Limited FY 2024 filings available
Nectar Biopharma Private Limited reported revenue of ₹2.6 Cr (down 38% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings of Nectar Biopharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Dec 2019 | Hdfc Bank Limited | ₹14.5 Lakh | Satisfied |
| 26 Feb 2019 | Others | ₹22.5 Cr | Satisfied |
Total charge records: 2 View all charges
Employees and EPFO Compliance at Nectar Biopharma Private Limited
View historical data on people associated with Nectar Biopharma Private Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Nectar Biopharma Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Nectar Biopharma Private Limited
GSTIN & GST Filing Data of Nectar Biopharma Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Nectar Biopharma Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Nectar Biopharma Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Nectar Biopharma Private Limited
MSME Payment Delays by Nectar Biopharma Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Nectar Biopharma Private Limited
Subsidiaries & Group Companies of Nectar Biopharma Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Nectar Biopharma Private Limited with ownership details.
MCA Filings & Documents of Nectar Biopharma Private Limited
MCA Filings & Documents of Nectar Biopharma Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Nectar Biopharma Private Limited
Frequently Asked Questions about Nectar Biopharma Private Limited
Nectar Biopharma Private Limited is an active private limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 13 April 2015 (11+ years old) and is registered under CIN U24100MH2015PTC314118. The company has 2 employees.
Nectar Biopharma Private Limited reported revenue of ₹2.6 Cr for FY 2025 (down 38.00% YoY).
The current directors of Nectar Biopharma Private Limited are:
The primary industry of Nectar Biopharma Private Limited is pharma. The company specifically operates in pharmaceutical retailers and distributors. The company is currently active in this sector.
Nectar Biopharma Private Limited can be reached at the registered office: Office No.101 1St Floor Udyog Bhavan Sonawala Lane Goregaon East, Mumbai, Maharashtra, India – 400063, or through the website necbio.com.
The authorised capital is ₹1 Cr, and the paid-up capital is ₹1 Cr.